Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Blood

• Publication date

  1990-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V76.9.1718.BLOODJOURNAL7691718PMID 2224121
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The in vivo metabolism of recombinant human erythropoietin in the rat.

  1989cited by this paper
• Comparative Pharmacokinetics of Recombinant Erythropoietin Administered by the Intravenous, Subcutaneous, and Intraperitoneal Routes in Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients

  1989cited by this paper
• Subcutaneous erythropoietin.

  1988cited by this paper
• Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy.

  1988cited by this paper
• Pharmacokinetics of erythropoietin in intact and anephric dogs.

  1988cited by this paper
• Subcutaneous erythropoietin.

  1988cited by this paper
• Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.

  1987cited by this paper
• Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen.

  1987cited by this paper
• Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

  1987cited by this paper
• Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

  1986cited by this paper
• Pharmacokinetics

  1982cited by this paper
• INFLUENCE OF DISAPPEARANCE RATE AND DISTRIBUTION SPACE ON PLASMA CONCENTRATION OF ERYTHROPOIETIN IN NORMAL RATS.

  1965cited by this paper
• PLASMA AND RENAL CLEARANCE OF EXOGENOUS ERYTHROPOIETIN IN THE DOG.

  1964cited by this paper

• Anemia Management in Pediatric Chronic Kidney Disease: Current Challenges and Treatment Strategies

  2025cites this paper
• Impact of Genetically Predicted Red Blood Cell Traits on Venous Thromboembolism: Multivariable Mendelian Randomization Study Using UK Biobank

  2020cites this paper
• Hematopoietic Growth Factors

  2019cites this paper
• A Randomized Controlled Trial: Regenerative Effects, Efficacy and Safety of Erythropoietin in Burn and Scalding Injuries

  2018cites this paper
• Anemia management in end stage renal disease patients undergoing dialysis: a comprehensive approach through machine learning techniques and mathematical modeling

  2016cites this paper
• Erythropoietin and thrombopoietin mimetics: Natural alternatives to erythrocyte and platelet disorders.

  2016cites this paper
• Mouse Models for Drug Discovery. Can New Tools and Technology Improve Translational Power?

  2016cites this paper
• Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States.

  2015cites this paper
• A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins

  2015cites this paper
• Erythropoietin reduces storage lesions and decreases apoptosis indices in blood bank red blood cells

  2015cites this paper
• Erythropoietin Stimulates Tumor Growth via EphB4.

  2015cites this paper
• The Effects of ARA290, an Erythropoietin Analogue, on Resting State Networks Associated with Depression: a randomized placebo-controlled trial

  2015cites this paper
• Effect of Erythropoietin on Microvascular Anastomosis in Rat

  2015cites this paper
• Cerebral blood flow control in small vessel disease

  2014cites this paper
• Diagnosis and treatment of cancer‐related anemia

  2014cites this paper
• Immunosuppressive effects of erythropoietin on human alloreactive T cells.

  2014cites this paper
• A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment

  2014cites this paper
• Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody

  2014cites this paper
• A Biomathematical Model of Human Erythropoiesis under Erythropoietin and Chemotherapy Administration

  2013cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents

  2013influential citation
• Hematopoietic Growth Factors: Focus on Erythropoiesis-Stimulating Agents

  2013cites this paper
• Population pharmacokinetic / pharmacodynamic analysis of erythropoiesis kinetics

  2012cites this paper
• Both acute and prolonged administration of EPO reduce cerebral and systemic vascular conductance in humans

  2012cites this paper
• Population Pharmacokinetic and Pharmacodynamic Model‐Based Comparability Assessment of a Recombinant Human Epoetin Alfa and the Biosimilar HX575

  2012influential citation
• A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Nonrenal Applications

  2012cites this paper
• Erythropoietin, but Not Asialoerythropoietin or Carbamyl-Erythropoietin, Attenuates Monocrotaline-Induced Pulmonary Hypertension in Rats

  2012cites this paper
• Erythropoiesis-stimulating agents.

  2011cites this paper
• Assessment of control and performance of biomedical systems

  2010cites this paper
• Cardiovascular effects of erythropoietin an update.

  2010cites this paper
• The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review.

  2010cites this paper
• Preventing Negative Effects of Smoking on Microarterial Anastomosis

  2010cites this paper
• Therapeutic levels of erythropoietin (EPO) achieved after gene electrotransfer to skin in mice

  2010cites this paper
• 2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

  2010cites this paper
• The pharmacokinetic profile of recombinant human erythropoietin is unchanged in patients undergoing cardiac surgery

  2009cites this paper
• Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia

  2009cites this paper
• Testing antidepressant compounds in a neuropsychological model of drug action

  2009influential citation
• Effects of recombinant human erythropoietin on mandibular distraction osteogenesis.

  2009cites this paper
• Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: an open-label, randomized-sequence, three-treatment, three-way crossover study.

  2009cites this paper
• Pharmacokinetics of erythropoiesis-stimulating agents

  2009cites this paper
• comments) hematologic disorders. Results of a phase I/II clinical trial (see Subcutaneous erythropoietin for treatment of refractory anemia in

  2009cites this paper
• Role of heme oxygenase-1 in the cardioprotective effects of erythropoietin during myocardial ischemia and reperfusion.

  2009cites this paper
• An Erythropoietin Autocrine/Paracrine Axis Modulates the Growth and Survival of Human Prostate Cancer Cells

  2009cites this paper
• Can we improve neurological outcomes in severe traumatic brain injury? Something old (early prophylactic hypothermia) and something new (erythropoietin).

  2009cites this paper
• A Phase I, Single and Fractionated, Ascending‐Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects

  2008cites this paper
• Evaluation of the Pharmacokinetics of Two Recombinant Human Erythropoietin Preparations: Epoetin Zeta and Epoetin Alfa

  2008cites this paper
• Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin preparations

  2008cites this paper
• Early high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: a matched control study.

  2008cites this paper
• Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel‐resistant phenotype

  2008cites this paper
• Population Pharmacokinetics Meta-Analysis of Recombinant Human Erythropoietin in Healthy Subjects

  2007cites this paper
• Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration

  2007cites this paper
• Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity

  2007cites this paper
• Oxygen breathing may be a cheaper and safer alternative to exogenous erythropoietin (EPO).

  2007cites this paper
• Recombinant human erythropoietin: has treatment reached its full potential?

  2006cites this paper
• Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: Results of a randomized, double-blind, placebo-controlled trial*

  2006cites this paper
• Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

  2006cites this paper
• Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells

  2006cites this paper
• Prospective randomized double-blind placebo controlled trial of recombinant human erythropoietin administration to reduce blood transfusions in anemic pediatric intensive care patients.

  2006cites this paper
• Effect of unadjusted dose of erythropoietin on hemoglobin in chronic renalfailure patients.

  2006cites this paper
• An endothelial metronome breast cancer

  2006cites this paper
• The prolonged half-lives of new erythropoietin derivatives via peptide addition.

  2006cites this paper
• The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin

  2005influential citation
• Changes in erythropoietin and haemoglobin concentrations in response to saturation diving

  2005cites this paper
• Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure

  2005cites this paper
• The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites

  2004influential citation
• Fc-erythropoietin fusion protein with improved pharmacokinetics

  2004cites this paper
• Treatment of anemia in patients with chronic heart failure.

  2004cites this paper
• Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers

  2004cites this paper
• Mechanisms and treatment of anemia in chronic heart failure.

  2004cites this paper
• 2004 Japanese Society for Dialysis Therapy Guidelines for Renal Anemia in Chronic Hemodialysis Patients *

  2004cites this paper
• Normal Erythropoietin Response in Chronic Hepatitis C Patients with Ribavirin-Induced Anaemia

  2003cites this paper
• Pharmacokinetic-Pharmacodynamic Modelling of Recombinant Human Erythropoietin in Athletes

  2003cites this paper
• Erythropoietin therapy in children with bronchiolitis and anemia*

  2003cites this paper
• Effect of Chronic and Short‐Term Erythropoietin Treatment on Random Flap Survival in Rats: An Experimental Study

  2003cites this paper
• Pharmacokinetic-Pharmacodynamic Modelling of Recombinant Human Erythropoietin in Athletes

  2003cites this paper
• Advances in therapeutics and diagnostics. Epoetin alfa.

  2003cites this paper
• Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control.

  2003cites this paper
• Clinical pharmacokinetic properties of rHuEPO: a review

  2003cites this paper
• Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes.

  2003cites this paper
• Pharmacokinetics/Pharmacodynamics of Recombinant Human Erythropoietins in Doping Control

  2003cites this paper
• The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP

  2002cites this paper
• Has the best route of administration for epoetin been established

  2002cites this paper
• rhEPO in hematopoietic stem cell mobilization, transplantation and in-vitro expansion

  2002cites this paper
• Erythropoietin Use in Pediatric Oncology

  2002cites this paper
• Perioperative use of erythropoietin.

  2002cites this paper
• Trends in anemia management among US hemodialysis patients.

  2002cites this paper
• Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin (rhEPO)

  2002cites this paper
• Epoetin omega for treatment of anemia in maintenance hemodialysis patients.

  2002cites this paper
• Detection of DNA-Recombinant Human Epoetin-Alfa as a Pharmacological Ergogenic Aid

  2002cites this paper
• Potential cost savings of erythropoietin administration in end-stage renal disease.

  2002cites this paper
• Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia.

  2001cites this paper
• Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.

  2001cites this paper
• IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000.

  2001cites this paper
• Erythropoietin use and abuse: When physiology and pharmacology collide.

  2001cites this paper
• Human immune response to recombinant human proteins.

  2001cites this paper
• Modelisation pharmacocinetique et pharmacodynamique d'administration d'erythropoietine

  2000cites this paper
• PHARMACOKINETICS OF SEVERAL SUBCUTANEOUS DOSES OF ERYTHROPOIETIN: POTENTIAL IMPLICATIONS FOR BLOOD TRANSFUSION

  2000cites this paper
• Haemoglobin, Blood Volume and Endurance

  2000cites this paper
• Clinical Applications of Recombinant Human Erythropoietin

  2000cites this paper
• Simulated moderate altitude elevates serum erythropoietin but does not increase reticulocyte production in well-trained runners

  2000cites this paper
• Physiological and pharmacodynamic considerations for route of EPO administration.

  2000cites this paper